TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
Journal Title
Cancer Discovery
Publication Type
epub ahead of print
Abstract
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML have lower response rates to either induction chemotherapy, hypomethylating agent-based regimens, or venetoclax-based therapies compared with non-TP53-mutated counterparts and a poor median overall survival of 5 to 10 months. Recent advances have identified novel pathogenic mechanisms in TP53-mutated myeloid malignancies, which have the potential to improve treatment strategies in this distinct clinical subgroup. In this review, we discuss recent insights into the biology of TP53-mutated MDS/AML, current treatments, and emerging therapies, including immunotherapeutic and nonimmune-based approaches for this entity. SIGNIFICANCE: Emerging data on the impact of cytogenetic aberrations, TP53 allelic burden, immunobiology, and tumor microenvironment of TP53-mutated MDS and AML are further unraveling the complexity of this disease. An improved understanding of the functional consequences of TP53 mutations and immune dysregulation in TP53-mutated AML/MDS coupled with dismal outcomes has resulted in a shift from the use of cytotoxic and hypomethylating agent-based therapies to novel immune and nonimmune strategies for the treatment of this entity. It is hoped that these novel, rationally designed combinations will improve outcomes in this area of significant unmet need.
Publisher
AACR
WEHI Research Division(s)
Blood Cells And Blood Cancer
PubMed ID
36218325
Open Access at Publisher's Site
https://doi.org/10.1158/2159-8290.CD-22-0332
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-10-14 09:03:00
Last Modified: 2022-10-14 09:03:42
An error has occurred. This application may no longer respond until reloaded. Reload 🗙